1. Adoni T, Lino AM, da Gama PD. . Recurrent neuromyelitis op-tica in brazilian patients: clinical, immunological, and neuro-imaging characteristics. Mult Scler J. 2010; 16:81–6.
Article
2. Sergio P, Mariana B, Alberto O. . Association of neuromyelitis optic (NMO) with autoimmune disorder: report of two cases and review of the literature. Clin Rheumatol. 2010; 29:1335–8.
3. Devic E. Myélite subaiguë compliquée de névrite optique. Bull Med (Paris). 1894; 8:1033–4.
4. Lee KW, Lee SJ, Lee JH. Neuromyelitis optica in children after ste-roid therapy. J Korean Ophthalmol Soc. 2004; 45:2088–92.
5. Kuroiwa Y. Vinken PJ, Bruyn GW, Klawans HL, editors. Neuromyelitis optica (Devic’s disease. Devic’s syndrome). Handbook of clinical neurology. Amsterdam: North-Holland Pub. Co;1985. v. 3.:p. p. 397–408.
6. Wingerchuk DM, Lennon VA, Lucchinettin CF. . The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6:805–15.
Article
7. Polgár A, Rózsa C, Müller V. . Devic’s syndrome and SLE: Challenges in diagnosis and therapeutic possibilities based on two overlapping cases. Autoimmun Rev. 2011; 10:171–4.
8. Weinshenker BG, Wingerchuk DM, Pittock SJ. . NMO-IgG: A specific biomarker for neuromyelitis optica. Dis Markers. 2006; 22:197–206.
Article
9. Weinshenker BG, Wingerchuk DM, Vukusic S. . Neuromyelitis optica IgG predicts relapse after longitudinally extensive trans-verse myelitis. Ann Neurol. 2006; 59:566–9.
Article
10. Jarius S, Paul F, Franciotta D. . Mechanisms of disease: aqua-porin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008; 4:202–14.
Article
11. Bergamaschi R, Ghezzi A. Devic’s neuromyelitis optica: clinical features and prognostic factors. Neurol Sci. 2004; 25(Suppl 4):S364–7.
Article
12. Sá MJ. Acute transverse myelitis: a practical reappraisal. Autoimmun Rev. 2009; 9:128–31.
Article
13. Noh Y, Kang EH, Hwang JM, Kim JS. Bilateral optic neuritis as the first manifestation of systemic lupus erythematosus associated with neuromyelitis optica. J Korean Neurol Assoc. 2010; 28:323–5.
14. Karim S, Majithia V. Devic’s syndrome as initial presentation of systemic lupus erythematosus. Am J Med Sci. 2009; 338:245–7.
Article
15. Mangat P, Ravindran J, Cleland L, Limaye V. A case of longitudi-nally extensive transverse myelitis (LETM): neuromyelitis optica. Clin Rheumatol. 2008; 27(Suppl 2):S67–9.
Article
16. Wingerchuk DM, Hogancamp WF, O’brien PC, Weinshenker BG.The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999; 53:1107–14.
Article
17. Keegan M, Pineda AA, McClelland RL. . Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58:143–6.
Article
18. Papeix C, Vidal JS, de Seze J. . Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007; 13:256–9.
Article
19. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007; 252:57–61.
Article
20. Wingerchuk DM, Weinshenker BG. Neuromyelitis. optica Curr Treat Options Neurol. 2005; 7:173–82.
21. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998; 51:1219–20.
Article
22. Weinstock-Guttman B, Ramanathan M, Lincoff N. . Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006; 63:957–63.
Article
23. Bakker J, Metz L. Devic’s neuromyelitis optica treated with intra-venous gamma globulin (IVIG). Can J Neurol Sci. 2004; 31:265–7.
Article
24. Cree BA, Lamb S, Morgan K. . An open label study of the ef-fects of rituximab in neuromyelitis optica. Neurology. 2005; 64:1270–2.
Article
25. Brinbaum J, Kerr D. Optic neuritis and recurrent myelitis in a wom-an with systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008; 4:381–6.
26. Mok CC, To CH, Mak A, Poon WL. Immunoablative CYC for re-fractory lupus-related neuromyelitis optica. J Rheumatol. 2008; 35:172–4.